Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Northland Capital Remains Positive on Edwards Lifesciences (EW) Long-Term Outlook
February 2, 2017 12:50 PM ESTNorthland Capital Markets analyst Suraj Kalia is sticking with her Outperform rating and $105 price target on Edwards Lifesciences (NYSE: EW) even though the company is hard time meeting lofty Street expectations.
Kalia commented, "Q4-16 revs @ $768M > consensus @ $758M & our estimate @ $763M. GAAP EPS @ $0.73 > our estimate @ $0.71 &... More
Leerink Partners Downgrades Edwards Lifesciences (EW) to Market Perform
February 2, 2017 9:34 AM ESTLeerink Partners downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $98.02 yesterday.
... MoreEdwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance
February 1, 2017 4:17 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.75, $0.03 better than the analyst estimate of $0.72. Revenue for the quarter came in at $767.7 million versus the consensus estimate of $759.54 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2017 EPS of $0.79-$0.89, versus the consensus of $0.81.... More
